Zydus Cadila gets USFDA nod to market generic cancer drug in US

The company has received final approval from the US Food and Drug Administration (USFDA) to Decitabine for Injection in the strength of 50 mg/vial single-dose vial, Zydus Cadila said in a statement. Decitabine is used to treat myelodysplastic syndromes, certain types of blood or bone marrow cancer.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/32jNIfP
via IFTTT